Latest Breaking News On - Aboutqualigentherapeutics inc - Page 1 : vimarsana.com

Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Qualigen Therapeutics Pan-RAS Inhibitor Program Highlighted in Two Abstracts at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesMichael poirierUniversity of louisville uofl research foundationQualigen therapeutics incJules abrahamjqa partners incQualigen incAboutqualigentherapeutics incUniversity of louisvilleAmerican society of clinical oncologyWall streetFeature preclinicaldataPancreatic cancerLuminalb breastOrphan drug designationAmerican societyClinical oncology

Qualigen Therapeutics Presents Data On QN-247 in Triple

In Vivo Efficacy Study Demonstrates QN-247 as Potential Therapeutic Approach in Rare Breast Cancer Type CARLSBAD, Calif., April 18, 2023 (GLOBE.

United statesAndrew hertigJules abrahamTariq arshadMichael poirierMarkj sarnoAmerican association for cancer researchAboutqualigentherapeutics incPartners incQualigen therapeutics incVivo efficacy study demonstratesPotential therapeutic approachRare breast cancerOrphan drug designationAmerican associationCancer research

Composition of Matter Patent for QN-302 Granted by United

CARLSBAD, Calif., March 21, 2023 (GLOBE NEWSWIRE) Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life sciences.

United statesJules abrahamMichael poirierExchange commissionEuropean patent officePartners incQualigen therapeutics incAboutqualigentherapeutics incTrademarks officeOrphan drug designationUnited states patentInvestigational new drugGastrointestinal stromal tumorsDrug designationQualigen therapeuticsFast track

Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules

Data on Potential Biomarker for Qualigen Therapeutics Lead Program QN-302 Published in Peer-Reviewed Journal Molecules
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesTariq arshadExchange commissionJules abrahamjqa partners incQualigen therapeutics incAboutqualigentherapeutics incWall streetGene expression may be markerAnti tumor activityOrphan drug designationChief medical officerQualigen therapeuticsFast trackOrphan drugPrivate securities litigation reform act

Qualigen Therapeutics Promotes Benedict M Abugan to Vice President, Head of Diagnostics and Corporate Communications

Qualigen Therapeutics Promotes Benedict M Abugan to Vice President, Head of Diagnostics and Corporate Communications
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoBenedict abuganQualigen fastpackMichael poirierBenedictm abuganUniversity of californiaCorporate communicationsJules abrahamjqa partners incQualigen therapeutics incAboutqualigentherapeutics incWall streetOrphan drug designationVice presidentBiosite diagnosticsAcon laboratories